Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Optimistically Ramping Up For Prasugrel Launch

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo CEO Takashi Shoda acknowledged during the company's third quarter results call that the delay in U.S. FDA approval of Effient (prasugrel), a novel platelet inhibitor that the company filed jointly with Eli Lilly in December 2007, has negatively affected the company net sales forecast

You may also be interested in...



Daiichi Sankyo/Lilly's Prasugrel Clears FDA

WASHINGTON - U.S. FDA is showing no evidence of summer doldrums - the agency has approved Daiichi Sankyo/Lilly's oral platelet inhibitor Effient (prasugrel)

Daiichi Sankyo/Lilly's Prasugrel Clears FDA

WASHINGTON - U.S. FDA is showing no evidence of summer doldrums - the agency has approved Daiichi Sankyo/Lilly's oral platelet inhibitor Effient (prasugrel)

Daiichi Sankyo’s Infringement Lawsuits Highlight Japan’s Generic Drug Tug-Of-War

Daiichi Sankyo waged patent infringement war against generic drug makers with lawsuits registered in two Japanese district courts March 23. The antibacterial drug Cravit (levofloxacin) lies at the center of the litigation brought by Daiichi Sankyo

Related Content

UsernamePublicRestriction

Register

ID1122434

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel